CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 180 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2021. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,071 | -30.6% | 693 | -14.4% | 0.00% | – |
| Q2 2023 | $27,479 | -15.9% | 810 | -10.8% | 0.00% | – |
| Q1 2023 | $32,665 | -22.2% | 908 | -5.9% | 0.00% | – |
| Q4 2022 | $42,000 | +44.8% | 965 | -6.7% | 0.00% | – |
| Q3 2022 | $29,000 | +3.6% | 1,034 | -1.0% | 0.00% | – |
| Q2 2022 | $28,000 | -12.5% | 1,044 | +6.7% | 0.00% | – |
| Q1 2022 | $32,000 | -13.5% | 978 | +4.2% | 0.00% | – |
| Q4 2021 | $37,000 | -24.5% | 939 | +3.0% | 0.00% | – |
| Q3 2021 | $49,000 | +58.1% | 912 | -1.1% | 0.00% | – |
| Q2 2021 | $31,000 | +72.2% | 922 | 0.0% | 0.00% | – |
| Q1 2021 | $18,000 | +12.5% | 922 | -1.4% | 0.00% | – |
| Q4 2020 | $16,000 | -20.0% | 935 | -29.9% | 0.00% | – |
| Q3 2020 | $20,000 | +17.6% | 1,334 | +1.0% | 0.00% | – |
| Q2 2020 | $17,000 | +1600.0% | 1,321 | +38.5% | 0.00% | – |
| Q1 2020 | $1,000 | – | 954 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |